Autopsy report · NCT01859351

Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours

“Study terminated for business reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 9 months before it stopped.
• 13 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Heidelberg Pharma AG

Sponsor type

Industry

Conditions

Advanced Solid Tumours

Interventions

WX-037; WX-554

Participants

13

Sites

3

Countries

United Kingdom

Trials that died the same way

• A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants
  “Study terminated due to business decision” (92% match in meaning)
• A Study of LY3549492 in Healthy Weight Adult Participants
  “Study terminated for strategic business reasons” (91% match in meaning)
• Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
  “Study terminated due to business priorities” (91% match in meaning)
• Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
  “Study terminated due to business and strategic decision.” (90% match in meaning)
• Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
  “The study was terminated due to a business decision.” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.